Sector: Chemicals

Latest content

Legal challenges to the PTAB’s NHK-Fintiv discretionary denial regime mount

Life sciences companies are among those leading the way in going to court to get the current rules struck down

20 August 2021

Brazil on the cusp of passing landmark compulsory technology transfer law

Life sciences innovators may be compelled to hand over trade secrets, data and biological materials under legislation that now only requires President Bolsonaro’s signature to become law

19 August 2021

A defensive strategy for China can help multinationals avoid bad faith patent litigation

Companies can take steps to reduce the chance that they’re targeted with a low-quality patent

19 August 2021

New study shows surge in data-driven and computer-assisted healthcare patents

Boom in digital healthcare and bioinformatics IP requires strategic adjustments in both the life sciences and high-tech arenas

17 August 2021

$235 million CAFC decision creates confusion around skinny-label generics, says dissenting judge

The Federal Circuit hands down its second ruling in the carvedilol dispute between Teva and GSK, following widespread concern over its first

13 August 2021

Chinese court enforces trade secret arbitration award of over $100 million against Chinese company

Dow and Johnson Matthey welcome enforcement action, which comes on the heels of a civil trade secrets litigation win in a different Chinese court last year

12 August 2021

Pharma should make good use of the UPC from the beginning, says Bayer’s head of IP

There are a lot of potential benefits to the new system, but we need to integrate it into our strategies to make sure it works, explains Joerg Thomaier

11 August 2021

US legislators have anti-competitive pharma IP strategies in their sights

There is now momentum behind several proposed pieces of legislation with implications for life sciences patents

06 August 2021

What’s behind the new patent litigation offensive from China’s top EV battery maker

Poached customers and trade secret worries underpin CATL’s patent suits against a domestic Chinese competitor

06 August 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams

05 August 2021

Get unlimited access to all IAM content